Article Versions Notes

Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend CM Jr., Anthony L, Wasilchenko C, Melton ML, et al. PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells. 2021; 10(5):1261. https://doi.org/10.3390/cells10051261

Chow, Zeta, Jeremy Johnson, Aman Chauhan, Tadahide Izumi, Michael Cavnar, Heidi Weiss, Courtney M. Townsend, Jr., Lowell Anthony, Carrigan Wasilchenko, Matthew L. Melton, and et al. 2021. "PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors" Cells 10, no. 5: 1261. https://doi.org/10.3390/cells10051261

Chow, Z., Johnson, J., Chauhan, A., Izumi, T., Cavnar, M., Weiss, H., Townsend, C. M., Jr., Anthony, L., Wasilchenko, C., Melton, M. L., Schrader, J., Evers, B. M., & Rychahou, P. (2021). PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells, 10(5), 1261. https://doi.org/10.3390/cells10051261